Recently, the State Drug Administration approved the marketing of rizabutinib tablets, a Class 1 innovative drug declared by Genzyme Corporation. This drug is used in adult patients with persistent or chronic primary immune thrombocytopenia who have had poor response or intolerance to treatment with glucocorticoids, immunoglobulins, etc. The launch of this drug provides patients with new treatment options.

Recently, the State Drug Administration approved the marketing of rizabutinib tablets, a Class 1 innovative drug declared by Genzyme Corporation. This drug is used in adult patients with persistent or chronic primary immune thrombocytopenia who have had poor response or intolerance to treatment with glucocorticoids, immunoglobulins, etc. The launch of this drug provides patients with new treatment options.